The ability of simvastatin to activate RyR1 may be common to other statins and could explain why cerivastatin, a compound removed from the market due to reports of rhabdomyolysis, was shown to trigger Ca2+ release from isolated skeletal SR vesicles (Inoue et al.,2003). The gene discussed is RYR1; the disease is rhabdomyolysis.